| Date | Title | Description |
| 29.10.2024 | AbbVie’s Bold Move: Acquiring Aliada Therapeutics for CNS Breakthroughs | In a strategic maneuver that echoes the age-old adage, "the early bird catches the worm," AbbVie has set its sights on the burgeoning field of central nervous system (CNS) therapeutics. The Chicago-based pharmaceutical giant annou... |
| 28.10.2024 | AbbVie to Acquire Aliada Therapeutics | AbbVie (NYSE: ABBV), Chicago, IL-based acquired Aliada Therapeutics, a Boston, MA-based biotechnology company focused on central nervous system (CNS) diseases.
AbbVie will acquire all outstanding Aliada equity for $1.4 Billion in cash, subj... |
| 27.10.2024 | How Worcester is Emerging as a Tech and Biotech Center | Share
Tweet
Share
Share
Email
Worcester, Massachusetts, has gained attention as an emerging hub for technology and biotechnology. Once known mainly for its industrial and manufacturing roots, Worcester is experiencing an economic and techno... |
| 19.10.2024 | Gland Pharma Welcomes New Leadership Amidst Industry Shifts | Gland Pharma is turning a new page. The company has appointed Shyamakant Giri as its new Chief Executive Officer, effective January 15, 2025. This move comes at a pivotal time for the pharmaceutical industry, which is undergoing rapid chang... |
| 18.10.2024 | Shyamakant Giri is new CEO of Gland Pharma | Gland Pharma’s Board has approved the appointment of Shyamakant Giri as the new Chief Executive Officer (CEO) of the Company. Mr. Giri is expected to join the Company with effect from January 15, 2025.
Giri is a business leader with over 25... |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 02.10.2024 | Biden vs. Trump: What the US Election Means for Drug Pricing | Ivor Campbell, CEO of Snedden Campbell
The global landscape for medical technology, biotechnology, and life sciences is on the cusp of seismic change.
The confluence of geopolitical tensions, economic uncertainty, and evolving social values... |
| 26.09.2024 | A Surfer Without a Degree Is Worth $16 Billion After His Biotech Company's Stock Soared 1,100% in a Year He took classes at UC Santa Barbara in the 1960s but didn't get a degree. Instead, he was focus... |
This article originally appeared on Business Insider.
A surfer without a college degree has gone from baking cookies to building robots, minting billions in biotech, and ranking among the world's richest people.
Bob Duggan, 80, is the co-C... |
| 19.09.2024 | Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024 | Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66).
PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- T... |
| 18.09.2024 | Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI | TAIPEI and SAN DIEGO, Sept. 18, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an I... |
| 13.09.2024 | Building Bridges: The Future of Workplaces in Taiwan and Beyond | In the bustling heart of Taipei, a celebration unfolded. The Best Workplaces™ in Taiwan 2024 Awards Ceremony took place at the luxurious W Hotel. This event was not just a gathering; it was a testament to the evolving landscape of work cult... |
| 13.09.2024 | From Us to All: Diversity, Equity, Inclusion Great Place to Work® Honors the Best Workplaces™ in Taiwan for 2024 | TAIPEI, Sept. 13, 2024 /PRNewswire/ -- Great Place to Work® is excited to announce the successful conclusion of the Best Workplaces™ in Taiwan 2024 Awards Ceremony, held at the W Hotel in Taipei. This event celebrated the remarkable achieve... |
| 11.09.2024 | 2024 10th Best Workplaces in Asia™ Unveiled by Great Place To Work® | GPTW, Surveyed in 15 Countries, 870 National List Companies, Total of 6.9 million Participants
"Tips to the Award: Inclusive, Sustainable Organizational Culture and Trust-Based Talent Management"
SEOUL, South Korea, Sept. 11, 2024... |
| 10.09.2024 | Accelerating Clinical Product Development through Centralized Content Work Streams, Upcoming Webinar Hosted by Xtalks | lifesciences.transperfect.com
In this free webinar, learn how centralizing localization of clinical documentation can drastically reduce timelines for global studies. Attendees will learn practical methods for leveraging technology automati... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 03.09.2024 | SKIES ACROSS NORTH AMERICA TO LIGHT UP THIS FALL IN SUPPORT OF BLOOD CANCER PATIENTS | The Leukemia & Lymphoma Society kicks off philanthropic campaign Light The Night; communities nationwide encouraged to learn why awareness and support is critical
RYE BROOK, N.Y., Sept. 3, 2024 /PRNewswire/ -- The Leukemia & Lymphom... |
| 03.09.2024 | General Anesthesia Drugs Market: Trends, Segmentation, and Future Outlook | Share
Tweet
Share
Share
Email
The global general anesthesia drugs market has been experiencing significant evolution, driven by advancements in medical technology, increasing surgical procedures, and a growing emphasis on patient safety and... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 29.08.2024 | The Future of Pharmaceuticals: Navigating Price Negotiations and Patient Access | The landscape of pharmaceuticals is shifting. The winds of change are blowing through Wall Street and the healthcare system alike. As the U.S. government prepares for drug price negotiations under the Inflation Reduction Act, the stakes are... |
| 29.08.2024 | Great Place To Work Announces the Best Workplaces in Asia™ 2024 Representing 6.9 Million Employee Experiences | HANOI, Vietnam, Aug. 29, 2024 /PRNewswire/ -- Today, Great Place To Work® announced its Best Workplaces in Asia™ for 2024. The list is based on confidential survey data, with over 2.7 million individual responses representing the experience... |
| 27.08.2024 | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology | Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
Tue, Aug 27, 2024 08:00 CET Report this content
Stockholm, August 27, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced toda... |
| 23.08.2024 | Ozempic on Wall Street's list for 2027 Medicare drug negotiations | Future of HealthOzempic on Wall Street's list for 2027 Medicare drug negotiations
By Michael ErmanAugust 23, 202412:06 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A box of Ozempic made by No... |
| 15.08.2024 | Health | US drug price measure to cut costs by $7.5 billion in 2026 | Astra said it will accept the price reductions so patients can get its drugs. AbbVie said in a statement that the IRA does nothing to benefit patients and will harm the long-term development of new drugs. Merck and Amgen didn’t immediately ... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 29.07.2024 | Pharma companies less concerned after hearing from US on negotiated prices for Medicare | Boards, Policy & RegulationRegulatory Oversight
Regulatory
Government Health Policy
Pharma companies less concerned after hearing from US on negotiated prices for Medicare
By Patrick Wingrove and Michael ErmanJuly 29, 20245:37 PM UTCUpd... |
| 29.07.2024 | Oisín Biotechnologies: $15 Million Raised To Mitigate Effects Of Age-Related Diseases | Oisín Biotechnologies (a privately held biotechnology company focused on mitigating the effects of age-related diseases) announced the first closing in a $15 million Series A funding round. AbbVie Ventures led the first close. And in connec... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge**
** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | CVS Caremark® defines future of pharmacy benefit management | CVS Caremark pledges to accelerate transparency, drive to lowest net cost prescription drugs, strengthen pharmacy relations, and deliver the best clinical care in pharmacy
WOONSOCKET, R.I., July 23, 2024 /PRNewswire/ -- CVS Caremark®, the n... |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson
Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| 16.07.2024 | AbbVie Announces New UK Vice President and General Manager | AbbVie Announces New UK Vice President and General Manager
Tue, Jul 16, 2024 10:45 CET Report this content
For UK trade and national media
Steve Hopkinson has been appointed UK Vice President and General Manager with effect from 1st August ... |
| 10.07.2024 | Frost & Sullivan Institute Honors Global Companies with the Enlightened Growth Leadership Best Practices Recognition, 2024 | SANTA CLARA, Calif., July 10, 2024 /PRNewswire/ -- The Frost & Sullivan Institute is excited to announce the winners of the 2024 Enlightened Growth Leadership Best Practices Recognition from the Americas. This prestigious accolade honor... |
| 03.07.2024 | Wormington & Bollinger: AbbVie, Inc.'s Zymaxid ™ Implicated in Product Liability Lawsuit Due to Risk of Serious Injury and Death | Lennie F. Bollinger (PRNewsfoto/AbbVie, Inc.)
AbbVie faces lawsuit over Zymaxid™.
MCKINNEY, Texas, July 2, 2024 /PRNewswire-PRWeb/ -- Wormington & Bollinger is actively reviewing product liability cases associated with antibiotic eyedro... |
| 28.06.2024 | AbbVie Acquires Celsius Therapeutics | AbbVie (NYSE: ABBV), a North Chicago, IL-based company developing medicines and solutions that solve serious health issues, announced the acquisition of Celsius Therapeutics, Inc., a Cambridge, MA-based privately held biotechnology company ... |
| 28.06.2024 | "From Us to All: Diversity, Equity, Inclusion" Great Place to Work® recognizes the Best Workplaces™ in Hong Kong for 2024 | HONG KONG, June 28, 2024 /PRNewswire/ -- Great Place to Work® proudly announces the successful conclusion of the Best Workplaces™ in Hong Kong 2024 Awards Ceremony, held at the W Hotel in West Kowloon on June 27, 2024. The ceremony celebrat... |
| 25.06.2024 | TPG: Significant Strategic Growth Investment In K2 Medical Research | Leading global alternative asset management firm TPG announced a significant strategic growth investment in K2 Medical Research, an integrated clinical trial site platform that specializes in central nervous system (CNS) trials for leading ... |
| 24.06.2024 | Wake-Up Call: New Patient Survey Reveals Parkinson’s Significantly Disrupts Sleep | Insomnia, restless legs syndrome, and REM sleep behavior disorder are just a few issues people living with Parkinson's contend with each night.
Today, the PD Avengers, a Global Alliance to End Parkinson's Disease, released groundbreaking da... |
| 18.06.2024 | Learn To Win: Enterprise SaaS Training Company Raises $30 Million | Learn to Win, a leading provider of personalized, predictive, and secure enterprise training software, announced it has raised an oversubscribed $30 million in Series A funding led by the Westly Group, with follow-on participation from Norw... |
| 11.06.2024 | BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients | For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence Gap
IRVINE, Calif., June 11, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVi... |
| 10.06.2024 | SMC Approves First Subcutaneous Bispecific Treatment Option Tepkinly[® ]▼(epcoritamab) for Adults with an Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy | SMC Approves First Subcutaneous Bispecific Treatment Option Tepkinly[® ]▼(epcoritamab) for Adults with an Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy
Mon, Jun 10, 2024 11:09 CET Report this content For the fi... |
| 30.05.2024 | US, UK in focus as pharma companies eye $31 billion exports in FY25 | - |
| 22.05.2024 | Patent reform could be the next big move to help bring down drug prices | figcaption>span]:font-sans">
After pitched battles over Medicare drug price negotiations, Congress may be pivoting to more bipartisan ground: overhaul of the patent system that allows brand-name drugs to delay competition for yea... |
| 14.05.2024 | VISTA Eye Specialist Celebrates Families and Vision with Vibrant Eye Carnival | PETALING JAYA, Malaysia, May 14, 2024 /PRNewswire/ -- VISTA Eye Specialist ('VISTA') is thrilled to announce its upcoming VISTA Parents' Day Eye Carnival ('Eye Carnival'), a celebration of family, wellness, and the gift of sight. This speci... |
| 13.05.2024 | Alucio™ Deepens AI Capabilities in Its Beacon Scientific Exchange Platform | Supercharging Scientific Exchange
Powerful New Advancements Will Streamline Content Discovery and Elevate Personalization
SAN FRANCISCO, May 13, 2024 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the lif... |
| 10.05.2024 | Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration | Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion
Broad GCase elevation achieved in NHPs, while signif... |
| 27.04.2024 | India becoming attractive for clinical trials, says pharma industry leaders | - |
| 24.04.2024 | Pharma exports rise around 10% to $27.9 billion, US biggest importer | - |
| 16.04.2024 | FDA, CDC Warn Against Fake, Mishandled Botox Injections | Aldohn Domingo, Tech Times 16 April 2024, 11:04 pm
Both the CDC and the FDA have begun investigating "counterfeit" or mishandled botox injections after multiple people in different states experienced harmful reactions to them.
In ... |
| 16.04.2024 | Counterfeit Botox blamed in 9-state outbreak of botulism-like illnesses | Biden administration investigating counterfeit botox injections in Florida, eight other states
Biden administration investigating counterfeit botox injections in Florida, eight other states 01:13
Dangerous counterfeit versions of botulinum ... |
| 12.04.2024 | Botox shots, possibly counterfeit, linked to botulism-like illnesses | Doctors warn about popular cosmetic procedure called Barbie Botox
Doctors warn about popular cosmetic procedure called Barbie Botox 02:28
Federal officials are trying to determine the source of Botox injections — some of the shots potential... |
| 11.04.2024 | AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults | AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults
Thu, Apr 11, 2024 08:00 CET Report this content
PRESS RELEASE - For UK consumer, medical and trade media only
The National Institute for Health ... |
| 25.03.2024 | AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition | AbbVie already has blockbuster drugs for ulcerative colitis, but that isn’t stopping the pharmaceutical giant from trying to expand its scope in this disease. To that end, the company is acquiring Landos Biopharma, a clinical-stage biotech ... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 17.03.2024 | A long-time bull who predicted this market rally warns that gains are unsustainable — but these 20 stocks can outperform anyway | Markets A long-time bull who predicted this market rally warns that gains are unsustainable — but these 20 stocks can outperform anyway
James Faris
2024-03-17T09:07:01Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The lett... |
| 17.03.2024 | AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site | US$223 million expansion will add biologics capacity to AbbVie manufacturing network
Singapore manufacturing site to grow to more than 500 employees following expansion
Construction will commence immediately with facilities becoming operati... |
| 15.03.2024 | World Sleep Day Sees Launch of Parkinson’s Disease SLEEP Survey | Insomnia, restless legs syndrome, and REM sleep behavior disorder are just a few issues people living with Parkinson's contend with each night.
Take the survey and get back to sheep, er... sleep.
PD Avengers brings awareness to the unknown ... |
| 13.03.2024 | Contraceptives Market Growth Soars: Aiming for $50.6 Billion by 2030 with 6.5% CAGR | AMR | Contraceptives Market Report
WILMINGTON, DELAWARE, UNITED STATES, March 13, 2024 /EINPresswire.com/ -- Allied Market Research has recently unveiled a research study titled "Contraceptives Market Outlook and Forecast 2020-2030." Th... |
| 13.03.2024 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update | – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales of $52.4 million in the fourth quarter and... |
| 13.03.2024 | После вмешательства генпрокурора РФ 68 южноуральцев обеспечены лекарствами | - |
| 12.03.2024 | Tellius Reveals GenAI Enhancements, Pioneering Enterprise Analytics and Insights | Tellius, theAI-native analytics company, unveiled a groundbreaking expansion of its generative AI (GenAI) features at the 2024 Gartner Data & Analytics Summit. The launch of GenAI-powered narratives and search, collaborative stories, an... |
| 11.03.2024 | AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease | AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease
Mon, Mar 11, 2024 12:12 CET Report this content
For Medical and Trade media.
... |
| 11.03.2024 | Contract Research And Manufacturing Services (CRAMS) Market Size, Share And Growth Analysis For 2024-2033 | Contract Research And Manufacturing Services (CRAMS) Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
The Business Research Company's Contract Research And Manufacturing Services (CRAMS) Global Market Report 20... |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein
-Advancing development candidate NDC-0524 into IND-enablin... |
| 08.03.2024 | Seladelpar (MBX-8025) Market Overview and Outlook 2024-2032: Product Overview, Regulatory Milestones, Global Activities, Patents, Market Assessment, Emerging Therapies, SWOT Analysis | - |
| 08.03.2024 | Psychedelic Drugs Market Size, Share And Growth Analysis For 2024-2033 | Psychedelic Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
The Business Research Company has updated all its market reports with the latest information for the year 2024, projecting trends and forecasts... |
| 08.03.2024 | Peptide Therapeutics Market Size, Share, Revenue, Trends And Drivers For 2024-2033 | Peptide Therapeutics Market Report 2024 – Market Size, Trends, And Forecast 2024-2033
The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033
The peptide therapeutics market s... |
| 08.03.2024 | Gynecology Drugs Market Size, Share And Growth Analysis For 2024-2033 | Gynecology Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2023-2032
The Business Research Company's Gynecology Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2023-2032
The Business Res... |
| 07.03.2024 | Rheumatoid Arthritis (RA) Patient Pool Analysis in APAC: Market Size and Forecast to 2034 | - |
| 05.03.2024 | Health | The new beauty regimen: Lose weight with Ozempic, tighten up with cosmetic surgery | Andrea Chang | Los Angeles Times (TNS)
LOS ANGELES — Jeniffer Brown wanted the Ozempic body. She just didn’t want “Ozempic face.”
She got both, dropping 20 pounds in the first four months after she started taking the blockbuster injectable ... |
| 04.03.2024 | Biopharmaceutical Innovations Lead the Way in Migraine Drugs Market Advancement | CAGR of 3.1% | Migraine is a clinical condition associated with painful headaches and other symptoms such as nausea, sensitivity to smell, and others.
PORTLAND, OREGON, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- Migraine drugs are medications that... |
| 04.03.2024 | Pharmaceutical Manufacturing Market Projected to Grow at 7.8% CAGR, Reaching $863.6 Bn by 2030 | Vantage Market Research | Vantage Market Research
Pharmaceutical Manufacturing Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2030 WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- The Global Pharma... |
| 01.02.2024 | NICE Recommends Subcutaneous Treatment Option Tepkinly[®]▼(epcoritamab) for Eligible* Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy | NICE Recommends Subcutaneous Treatment Option Tepkinly[®]▼(epcoritamab) for Eligible* Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy
Thu, Feb 01, 2024 09:48 CET Report this content
For the first time... |
| 26.01.2024 | AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site | US$223 million expansion will add biologics capacity to AbbVie manufacturing network
Singapore manufacturing site to grow to more than 500 employees following expansion
Construction will commence immediately with facilities becoming operati... |
| 06.12.2023 | AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies | Collaboration to leverage BigHat’s Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie’s expertise in Oncology and Neuroscience to develop next-generation antibodies
AbbVie Inc. and BigHat Biosciences, ... |
| 30.11.2023 | AbbVie Acquires ImmunoGen, for Approx. $10.1 Billion | AbbVie (NYSE: ABBV) acquired ImmunoGen (NASDAQ: IMGN), a Waltham, MA-based company developing antibody-drug conjugates (ADCs), for approx. $10.1 Billion.
The boards of directors of both companies have approved the transaction, which is expe... |
| 01.11.2023 | いい歳をとりたい女性の「しわ・たるみ」の悩みに正しい知識を『いい歳とり隊』サポート強化月間 始動 | 加齢とともに肌悩みは変化し、スキンケアでは解決できない「しわ・たるみ」の肌悩みが気になる方も多いのではないでしょうか。「女性の顔の肌悩み（2023）」調査（*1）によると40代から「しわ・たるみ」がTOP3に、50代・60代以上では「たるみ」が1位という結果となり、年齢を重ねるに伴って「しわ・たるみ」への悩みを持つ女性が増えていくということがわかりました。そのような「しわ・たるみ」の悩みを抱えているすべての女性の肌悩みを解決すべく、アッヴィ合同会社 アラガン・エステティックス... |
| 24.10.2023 | MHRA Grants Conditional Marketing Authorisation for Tepkinly[®]▼(epcoritamab) as a Bispecific Treatment for Adults with Relapsed or Refractory DLBCL After Two or More Lines of Systemic Therapy | MHRA Grants Conditional Marketing Authorisation for Tepkinly[®]▼(epcoritamab) as a Bispecific Treatment for Adults with Relapsed or Refractory DLBCL After Two or More Lines of Systemic Therapy
Tue, Oct 24, 2023 11:55 CET Report this content... |
| 09.10.2023 | AbbVie’s AQUIPTA[®]▼ (atogepant) Is Now Available In Scotland For The Prevention Of Migraines In Adults | AbbVie’s AQUIPTA[®]▼ (atogepant) Is Now Available In Scotland For The Prevention Of Migraines In Adults
Mon, Oct 09, 2023 11:02 CET Report this content
PRESS RELEASE - For UK consumer, medical and trade media only
The Scottish Medicines Con... |
| 04.09.2023 | AbbVie’s AQUIPTA[®]▼(atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults | AbbVie’s AQUIPTA[®]▼(atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults
Mon, Sep 04, 2023 01:05 CET Report this content
PRESS RELEASE - For UK consumer, trade and medical media only
The oral, once-dai... |
| 13.08.2023 | Excellence In Science And Math Runs In The Family | The Geneus Family in Cap and Gown at Olivia Geneus's PhD graduation from SUNY at Buffalo.Photo Credit: Alexander Harold |
| 12.06.2023 | SMC Accepts RINVOQ[®]▼ (upadacitinib) as a Treatment Option for Adults with Moderately to Severely Active Crohn’s Disease in Scotland | SMC Accepts RINVOQ[®]▼ (upadacitinib) as a Treatment Option for Adults with Moderately to Severely Active Crohn’s Disease in Scotland
Mon, Jun 12, 2023 16:29 CET Report this content
PRESS RELEASE - For Scottish Consumer, Medical and Industr... |
| 18.05.2023 | NICE Recommends RINVOQ[®]▼(upadacitinib) as a Treatment Option for Moderately to Severely Active Crohn’s Disease | NICE Recommends RINVOQ[®]▼(upadacitinib) as a Treatment Option for Moderately to Severely Active Crohn’s Disease
Thu, May 18, 2023 10:04 CET Report this content
PRESS RELEASE - For UK Consumer, Medical and Industry Trade Media Only Upadacit... |
| 13.02.2023 | Despite Retro Name, Health Datapalooza Looks Ahead To Patient-Centered Digital Future | Health Datapalooza, organized by AcademyHealth, focuses on digital health innovations impacting ... [+] patient care.AcademyHealth |
| 01.02.2023 | MHRA Approves RINVOQ[®]▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease | MHRA Approves RINVOQ[®]▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease
Wed, Feb 01, 2023 16:00 CET Report this content
PRESS RELEASE - For UK Consumer Health, Medical and Tr... |
| 12.12.2022 | Scottish Medicines Consortium (SMC) Extends Advice Accepting RINVOQ®▼(upadacitinib) For Treatment of Adults with Moderate Rheumatoid Arthritis | Scottish Medicines Consortium (SMC) Extends Advice Accepting RINVOQ®▼(upadacitinib) For Treatment of Adults with Moderate Rheumatoid Arthritis
Mon, Dec 12, 2022 15:24 CET Report this content
Upadacitinib, a once daily pill, which was previo... |
| 25.11.2022 | NICE recommends RINVOQ[®]▼ (upadacitinib) As Treatment Option For Moderately to Severely Active Ulcerative Colitis in Adults | NICE recommends RINVOQ[®]▼ (upadacitinib) As Treatment Option For Moderately to Severely Active Ulcerative Colitis in Adults
Fri, Nov 25, 2022 09:53 CET Report this content
PRESS RELEASE - For UK Medical and trade media only
The NICE recomm... |
| 12.10.2022 | Allergan Aesthetics Pledges Diamond Level Sponsorship for 2022 Breast Reconstruction Awareness Day | ARLINGTON HEIGHTS, Ill. (PRWEB) October 12, 2022
The American Society of Plastic Surgeons (ASPS), the world’s largest organization of board-certified plastic surgeons, today announced Allergan Aesthetics, an AbbVie Company, will participate... |
| 17.08.2022 | NICE Recommends RINVOQ[®]▼(upadacitinib) As A Treatment Option For Active Ankylosing Spondylitis (AS) In Adults | NICE Recommends RINVOQ[®]▼(upadacitinib) As A Treatment Option For Active Ankylosing Spondylitis (AS) In Adults
Wed, Aug 17, 2022 16:20 CET Report this content Publication of a positive Final Appraisal Document (FAD) means RINVOQ®▼(upadacit... |
| 17.08.2022 | Global Dermal Fillers Market Vendor Landscape and Geographical Augmentation 2022-2029 | Dermal Fillers
Global Dermal Fillers market size is estimated to be USD 8.74 billion in 2029 from USD 5.31 Billion in 2022, with a CAGR change of 7.4% between 2022 to 2029. NEW YORK, NY, UNITED STATES, August 17, 2022 /EINPresswire.com/ -- ... |
| 11.08.2022 | NICE Recommendation Expands Patient Eligibility for AbbVie’s Ozurdex[® ](dexamethasone 0.7mg intravitreal implant) in Diabetic Macular Oedema (DMO) | NICE Recommendation Expands Patient Eligibility for AbbVie’s Ozurdex[® ](dexamethasone 0.7mg intravitreal implant) in Diabetic Macular Oedema (DMO)
Thu, Aug 11, 2022 19:31 CET Report this content
PRESS RELEASE - For UK medical and trade med... |
| 26.07.2022 | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults
Tue, Jul 26, 2022 18:03 CET Report this content
PRESS RELEASE - For UK medical and trade media only
Ulcerative colitis (UC... |
| 26.07.2022 | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults | MHRA Approves RINVOQ®▼ (upadacitinib) For the Treatment of Moderately to Severely Active Ulcerative Colitis in Adults
Tue, Jul 26, 2022 17:03 CET Report this content
PRESS RELEASE - For UK medical and trade media only
Ulcerative colitis (UC... |
| 13.07.2022 | AbbVie Employees in Asia Volunteer in Annual Week of Possibilities to Support 2,266 Members of the Community | Employees in Asia joined the global efforts to make a difference in local communities.
Employees across 8 locations in Asia contributed a total of 1,870 service hours, supporting 2,266 people.
The teams across the region organized 18 volunt... |
| 29.06.2022 | NICE recommends AbbVie’s RINVOQ[®▼ (upadacitinib) for use in adults and adolescents 12 years and older with moderate to severe atopic dermatitis (eczema)] | NICE recommends AbbVie’s RINVOQ[®▼ (upadacitinib) for use in adults and adolescents 12 years and older with moderate to severe atopic dermatitis (eczema)]
Wed, Jun 29, 2022 12:13 CET Report this content
Press release key messages:
Adults an... |
| 09.05.2022 | Scottish Medicines Consortium Accepts Chemotherapy-free Combination Treatment VENCLYXTO[®]▼(Venetoclax) Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia | Scottish Medicines Consortium Accepts Chemotherapy-free Combination Treatment VENCLYXTO[®]▼(Venetoclax) Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia
Mon, May 09, 2022 15:00 CET Report this content
Patients in Sco... |
| 19.04.2022 | People with Moderate to Severe Uncontrolled Crohn’s Disease Granted Early Access to New Investigational Treatment in the UK | People with Moderate to Severe Uncontrolled Crohn’s Disease Granted Early Access to New Investigational Treatment in the UK
Tue, Apr 19, 2022 12:01 CET Report this content
The Medicines and Healthcare Products Regulatory Agency (MHRA) has g... |
| 11.04.2022 | Scottish Medicines Consortium accepts AbbVie’s RINVOQ[®▼] (upadacitinib) for Use in Adolescents and Adults with Active Atopic Dermatitis (eczema) | Scottish Medicines Consortium accepts AbbVie’s RINVOQ[®▼] (upadacitinib) for Use in Adolescents and Adults with Active Atopic Dermatitis (eczema)
Mon, Apr 11, 2022 15:00 CET Report this content
Scotland the first nation in the UK to provide... |
| 11.04.2022 | Scottish Medicines Consortium Accepts VENCLYXTO[®]▼(venetoclax) Combination in Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia | Scottish Medicines Consortium Accepts VENCLYXTO[®]▼(venetoclax) Combination in Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia
Mon, Apr 11, 2022 15:00 CET Report this content
For the first time in Scotland, venetoclax in c... |
| 18.03.2022 | Botox maker AbbVie suspends operations in Russia | Russians will have to cope without their Botox — an injectable drug that smooths wrinkles — as long as President Vladimir Putin continues his country's attack on Ukraine.
Botox maker AbbVie, a global pharmaceutical company, said in a statem... |
| 06.03.2022 | AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion | AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cogni... |
